154 related articles for article (PubMed ID: 9094450)
1. DNA vaccines -- a modern gimmick or a boon to vaccinology?
Manickan E; Karem KL; Rouse BT
Crit Rev Immunol; 1997; 17(2):139-54. PubMed ID: 9094450
[TBL] [Abstract][Full Text] [Related]
2. DNA Vaccines - A Modern Gimmick or a Boon to Vaccinology?
Manickan E; Karem KL; Rouse BT
Crit Rev Immunol; 2017; 37(2-6):483-498. PubMed ID: 29773031
[TBL] [Abstract][Full Text] [Related]
3. DNA vaccines: a review.
Lewis PJ; Babiuk LA
Adv Virus Res; 1999; 54():129-88. PubMed ID: 10547676
[TBL] [Abstract][Full Text] [Related]
4. DNA vaccines: capacity to induce auto-immunity and tolerance.
Klinman DM; Takeshita F; Kamstrup S; Takeshita S; Ishii K; Ichino M; Yamada H
Dev Biol (Basel); 2000; 104():45-51. PubMed ID: 11713823
[TBL] [Abstract][Full Text] [Related]
5. DNA vaccines.
Donnelly JJ; Ulmer JB; Shiver JW; Liu MA
Annu Rev Immunol; 1997; 15():617-48. PubMed ID: 9143702
[TBL] [Abstract][Full Text] [Related]
6. DNA vaccines: a ray of hope.
Tuteja R
Crit Rev Biochem Mol Biol; 1999; 34(1):1-24. PubMed ID: 10090468
[TBL] [Abstract][Full Text] [Related]
7. DNA vaccines and intradermal vaccination by DNA tattooing.
Oosterhuis K; van den Berg JH; Schumacher TN; Haanen JB
Curr Top Microbiol Immunol; 2012; 351():221-50. PubMed ID: 21107792
[TBL] [Abstract][Full Text] [Related]
8. DNA vaccines: technology and application as anti-parasite and anti-microbial agents.
Alarcon JB; Waine GW; McManus DP
Adv Parasitol; 1999; 42():343-410. PubMed ID: 10050276
[TBL] [Abstract][Full Text] [Related]
9. Immune responses to DNA vaccines.
Kowalczyk DW; Ertl HC
Cell Mol Life Sci; 1999 May; 55(5):751-70. PubMed ID: 10379361
[TBL] [Abstract][Full Text] [Related]
10. Suppression of murine cytomegalovirus (MCMV) replication with a DNA vaccine encoding MCMV M84 (a homolog of human cytomegalovirus pp65).
Morello CS; Cranmer LD; Spector DH
J Virol; 2000 Apr; 74(8):3696-708. PubMed ID: 10729145
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with DNA encoding internal proteins of influenza virus does not require CD8(+) cytotoxic T lymphocytes: either CD4(+) or CD8(+) T cells can promote survival and recovery after challenge.
Epstein SL; Stack A; Misplon JA; Lo CY; Mostowski H; Bennink J; Subbarao K
Int Immunol; 2000 Jan; 12(1):91-101. PubMed ID: 10607754
[TBL] [Abstract][Full Text] [Related]
12. Liposomal vaccine formulations as prophylactic agents: design considerations for modern vaccines.
De Serrano LO; Burkhart DJ
J Nanobiotechnology; 2017 Nov; 15(1):83. PubMed ID: 29149896
[TBL] [Abstract][Full Text] [Related]
13. [Genetic vaccines].
Logunov DIu; Naroditskiĭ BS; Gintsburg AL; Vorob'ev AA
Vestn Ross Akad Med Nauk; 2005; (1):14-9. PubMed ID: 15715149
[TBL] [Abstract][Full Text] [Related]
14. Antibody and cellular immune responses following DNA vaccination and EHV-1 infection of ponies.
Soboll G; Hussey SB; Whalley JM; Allen GP; Koen MT; Santucci N; Fraser DG; Macklin MD; Swain WF; Lunn DP
Vet Immunol Immunopathol; 2006 May; 111(1-2):81-95. PubMed ID: 16549215
[TBL] [Abstract][Full Text] [Related]
15. Dose dependence of CTL precursor frequency induced by a DNA vaccine and correlation with protective immunity against influenza virus challenge.
Fu TM; Guan L; Friedman A; Schofield TL; Ulmer JB; Liu MA; Donnelly JJ
J Immunol; 1999 Apr; 162(7):4163-70. PubMed ID: 10201942
[TBL] [Abstract][Full Text] [Related]
16. DNA vaccines against enteric infections.
Herrmann JE
Vaccine; 2006 May; 24(18):3705-8. PubMed ID: 16095769
[TBL] [Abstract][Full Text] [Related]
17. Parenteral Vaccination Can Be an Effective Means of Inducing Protective Mucosal Responses.
Clements JD; Freytag LC
Clin Vaccine Immunol; 2016 Jun; 23(6):438-441. PubMed ID: 27122485
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant activity of fish type I interferon shown in a virus DNA vaccination model.
Chang CJ; Sun B; Robertsen B
Vaccine; 2015 May; 33(21):2442-8. PubMed ID: 25865470
[TBL] [Abstract][Full Text] [Related]
19. Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice.
Luo M; Tao P; Li J; Zhou S; Guo D; Pan Z
J Virol Methods; 2008 Dec; 154(1-2):121-7. PubMed ID: 18789973
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
